Komori
Alfresa Holdings (2784) · FactFirst stated

FY2025-H1 Revenue Growth and Lower Operating Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Revenue growth and profit decline in the medical-related businessA theme 2 companies write about · 7 as a headwind · 0 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「当セグメントの当中間連結会計期間の業績は、2024年４月に実施された薬価改定によるマイナス影響はあったものの、市場の伸長、なかでも特許品・新薬創出加算品等の販売増加および売上総利益率改善への取り組み等により増収および売上総利益は増益となりました。一方で、人件費、物流費および減価償却費等のコスト増により、売上高1兆2,965億88百万円(前年同期比2.3％増)、営業利益126億58百万円(同8.2％減)となりました。」

    市場伸長、特許品・新薬創出加算品等の販売増および売上総利益率改善により増収・売上総利益増となった一方、人件費・物流費・減価償却費等のコスト増により営業減益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.